Antihypertensive Drugs Market to Exceed USD 40 billion by 2031, Evolving at a CAGR of 3% - Exclusive Report by Transparency Market Research
October 11, 2023 03:16 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global antihypertensive drugs market is expected to develop at a CAGR of 3.0% from 2021...
Antihypertensive Drugs Market Projected to Expand at a CAGR of 3.0% from 2022 to 2030, Data by Contrive Datum Insights
January 16, 2023 08:58 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The Antihypertensive Drugs Market is estimated to reach a valuation of USD 30.2 Billion by 2022, growing at 3.0% CAGR during the assessment period...
Analysis of Global Antihypertensive Drugs Market Portrays Revenue of USD 40 Billion by 2031 and CAGR of ~3% During 2022-2031 – Kenneth Research
October 17, 2022 06:59 ET
|
Kenneth Research
New York, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Kenneth Research has published a detailed market report on the “Global Antihypertensive Drugs Market” for the forecast period, i.e., 2022-2031, which...
Antihypertensive Drugs Market Report Up to 2031: Visiongain Research Inc
February 28, 2022 10:00 ET
|
Visiongain Ltd
Visiongain has published a new report on Antihypertensive Drugs Market Report 2021-2031: Forecasts By Drug (Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers,...
Antihypertensive drugs Market to Garner $28.79 Billion by 2026
February 19, 2020 11:21 ET
|
Allied Market Research
Portland, OR, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The antihypertensive drugs industry was pegged at $22.56 billion in 2018, and is estimated to reach $28.79 billion by 2026, growing at a CAGR of 3.1%...
Anti-Hypertensive Drugs Market to Exceed USD 41,123.2 Million by 2023, at 2.67% CAGR, Say Market Research Future
April 11, 2019 04:12 ET
|
Market Research Future
Pune, India, April 11, 2019 (GLOBE NEWSWIRE) -- The Anti-hypertensive Drugs Market is expected to experience a moderate CAGR of 2.67% during the forecast period (2018-2023) with the valuation...